Cardioprotection by ivabradine through heart rate reduction and beyond

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 16, Issue 3-4, 2011, Pages 281-284

  Heusch, Gerd ^a   Skyschally, Andreas ^a   Schulz, Rainer ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

acute myocardial infarction; experimental cardiology; heart disease; ischemia reperfusion injury

Indexed keywords

AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; IVABRADINE;

CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; CORONARY ARTERY DISEASE; DRUG MECHANISM; DRUG SELECTIVITY; HEART FAILURE; HEART MUSCLE BLOOD FLOW; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART RATE; HUMAN; NONHUMAN; PRIORITY JOURNAL; SPECIES DIFFERENCE; STABLE ANGINA PECTORIS;

ANIMALS; BENZAZEPINES; BRADYCARDIA; CARDIOTONIC AGENTS; HEART RATE; HUMANS; ISCHEMIA;

EID: 80051481733     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248411405383     Document Type: Conference Paper

References (35)

1. Heusch G. Nitroglycerin and delayed preconditioning in humans. Yet another new mechanism for an old drug?. Circulation. 2001 ; 103 (24). 2876-2878 (Pubitemid 32578120)
2. Schulz R, Cohen MV, Behrends M, Downey JM, Heusch G. Signal transduction of ischemic preconditioning. Cardiovasc Res. 2001 ; 52 (2). 181-198 (Pubitemid 33000395)
3. Skyschally A, Schulz R, Heusch G. Pathophysiology of myocardial infarction: protection by ischemic pre-and postconditioning. Herz. 2008 ; 33 (2). 88-100 (Pubitemid 351437850)
4. Heusch G, Boengler K, Schulz R. Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation. 2008 ; 118 (19). 1915-1919
5. Hausenloy DJ, Baxter G, Bell R, et al. Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations. Basic Res Cardiol. 2010 ; 105 (6). 677-686
6. Ovize M, Baxter GF, Di Lisa F, et al. Postconditioning and protection from reperfusion injury: where do we stand?. Cardiovasc Res. 2010 ; 87 (3). 406-423
7. Heusch G. Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents. Br J Pharmacol. 2008 ; 153 (8). 1589-1610
8. Heusch G. Heart rate and heart failure. Circ J. 2011 ; 75 (2). 229-236
9. Heusch G, Skyschally A, Gres P, van Caster P, Schilawa D, Schulz R. Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine-protection beyond heart rate reduction. Eur Heart J. 2008 ; 29 (18). 2265-2275
10. Custodis F, Schirmer SH, Baumhakel M, Heusch G, Bohm M, Laufs U. Vascular pathophysiology in response to increased heart rate. J Am Coll Cardiol. 2010 ; 56 (24). 1973-1983
11. Schulz R, Rose J, Skyschally A, Heusch G. Bradycardic agent UL-FS 49 attenuates ischemic regional dysfunction and reduces infarct size in swine: comparison with the beta-blocker atenolol. J Cardiovasc Pharmacol. 1995 ; 25 (2). 216-228
12. Guth BD, Heusch G, Seitelberger R, Ross Jr. J. Mechanism of beneficial effect of beta-adrenergic blockade on exercise-induced myocardial ischemia in conscious dogs. Circ Res. 1987 ; 60 (5). 738-746 (Pubitemid 17098139)
13. Heusch G. α-Adrenergic mechanisms in myocardial ischemia. Circulation. 1990 ; 81 (1). 1-13
14. Heusch G, Baumgart D, Camici P, et al. α-Adrenergic coronary vasoconstriction and myocardial ischemia in humans. Circulation. 2000 ; 101 (6). 689-694 (Pubitemid 30094742)
15. Heusch G, Deussen A. Nifedipine prevents sympathetic vasoconstriction distal to severe coronary stenoses. J Cardiovasc Pharmacol. 1984 ; 6 (3). 378-383 (Pubitemid 14109185)
16. Heusch G, Guth BD, Seitelberger R, Ross J. Attenuation of exercise-induced myocardial ischemia in dogs with recruitment of coronary vasodilator reserve by nifedipine. Circulation. 1987 ; 75 (2). 482-490 (Pubitemid 17007357)
17. Heusch G. Myocardial stunning: a role for calcium antagonists during ischaemia?. Cardiovasc Res. 1992 ; 26 (1). 14-19
18. Borer JS. Drug insight: If inhibitors as specific heart-rate-reducing agents. Nature. 2004 ; 1 (2). 103-109 (Pubitemid 40823707)
19. DiFrancesco D, Camm JA. Heart rate lowering by specific and selective If current inhibition with ivabradine. A new therapeutic perspective in cardiovascular disease. Drugs. 2004 ; 64 (16). 1757-1765 (Pubitemid 39215187)
20. Guth BD, Heusch G, Seitelberger R, Ross J. Elimination of exercise-induced regional myocardial dysfunction by a bradycardic agent in dogs with chronic coronary stenosis. Circulation. 1987 ; 75 (3). 661-669 (Pubitemid 17026059)
21. Mulder P, Barbier S, Chagraoui A, et al. Long-term heart rate reduction induced by the selective If current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation. 2004 ; 109 (13). 1674-1679 (Pubitemid 38451726)
22. Dedkov EI, Zheng W, Christensen LP, Weiss RM, Mahlberg-Gaudin F, Tomanek RJ. Preservation of coronary reserve by ivabradine-induced reduction in heart rate in infarcted rats is associated with decrease in perivascular collagen. Am J Physiol Heart Circ Physiol. 2007 ; 293 (1). H590-H598
23. Borer JS, Fox K, Jaillon P, Lerebours G. Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina. Circulation. 2003 ; 107 (6). 817-823
24. Tardif J-C, Ford I, Tendera M, Bourassa MG, Fox K. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005 ; 26 (23). 2529-2536 (Pubitemid 41677303)
25. Ruzyllo W, Tendera M, Ford I, Fox KM. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs. 2007 ; 67 (3). 393-405 (Pubitemid 46425552)
26. Tardif JC, Ponikowski P, Kahan T. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J. 2009 ; 30 (5). 540-548
27. Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008 ; 372 (9641). 807-816
28. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J. 2009 ; 30 (19). 2337-2345
29. Heusch G. A BEAUTIFUL lesson-ivabradine protects from ischaemia, but not from heart failure: through heart rate reduction or more?. Eur Heart J. 2009 ; 30 (19). 2300-2301
30. Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010 ; 376 (9744). 875-885
31. Cerbai E, Sartiani L, DePaoli P, et al. The properties of the pacemaker current If in human ventricular myocytes are modulated by cardiac disease. J Mol Cell Cardiol. 2001 ; 33 (3). 441-448 (Pubitemid 32539001)
32. Michels G, Brandt MC, Zagidullin N, et al. Direct evidence for calcium conductance of hyperpolarization-activated cyclic nucleotide-gated channels and human native If at physiological calcium concentrations. Cardiovasc Res. 2008 ; 78 (3). 466-475 (Pubitemid 351769763)
33. Heusch G, Skyschally A, Schulz R. The in-situ pig heart with regional ischemia/reperfusion-ready for translation. J Mol Cell Cardiol. 2011 ;:
34. Skyschally A, van Caster P, Boengler K, et al. Ischemic postconditioning in pigs: no causal role for RISK activation. Circ Res. 2009 ; 104 (1). 15-18
35. Skyschally A, van Caster P, Iliodromitis EK, Schulz R, Kremastinos DT, Heusch G. Ischemic postconditioning-experimental models and protocol algorithms. Basic Res Cardiol. 2009 ; 104 (5). 469-483